Hims & Hers Health夜盘大跌近8%，FDA终止复方仿制药上市政策

异动解读

22 May

5月22日，数字医疗保健公司Hims & Hers Health Inc.（股票代码：HIMS）在周三夜盘交易中遭遇重创，股价大跌近8%。这一显著下跌引发了市场的广泛关注，投资者们纷纷猜测其背后的原因。

分析人士指出，此次股价下跌可能与近期减肥药市场的重大政策变化有关。大型保险公司Cigna宣布将在其药房福利管理计划中引入新条款，为使用热门减肥药Wegovy和Zepbound的患者提供每月200美元的自付费用上限。这一举措可能会影响到Hims & Hers等公司在竞争激烈的减肥药市场中的地位，从而引发投资者对公司未来业绩的担忧。

此外，美国食品和药物管理局（FDA）允许销售复方制剂Wegovy和Zepbound的政策将于5月22日结束，这一变化可能会直接影响Hims & Hers等公司销售这些产品的能力。随着政策环境的变化，投资者似乎正在重新评估公司的业务前景，导致股价出现明显下跌。然而，目前Hims & Hers Health尚未就股价变动发表官方声明，具体影响还有待进一步观察。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148052920"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148052920\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1148052920?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-05-22 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148052920","market":"nz","top_or_hot":-1,"title":"Hims & Hers Health夜盘大跌近8%，FDA终止复方仿制药上市政策","media":"异动解读","content":"<html><head></head><body><p>5月22日，数字医疗保健公司Hims &amp; Hers Health Inc.（股票代码：HIMS）在周三夜盘交易中遭遇重创，股价大跌近8%。这一显著下跌引发了市场的广泛关注，投资者们纷纷猜测其背后的原因。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/855466511362b16d9ef396717e875486\" tg-width=\"865\" tg-height=\"831\"/></p><p>分析人士指出，此次股价下跌可能与近期减肥药市场的重大政策变化有关。大型保险公司Cigna宣布将在其药房福利管理计划中引入新条款，为使用热门减肥药Wegovy和Zepbound的患者提供每月200美元的自付费用上限。这一举措可能会影响到Hims &amp; Hers等公司在竞争激烈的减肥药市场中的地位，从而引发投资者对公司未来业绩的担忧。</p><p>此外，美国食品和药物管理局（FDA）允许销售复方制剂Wegovy和Zepbound的政策将于5月22日结束，这一变化可能会直接影响Hims &amp; Hers等公司销售这些产品的能力。随着政策环境的变化，投资者似乎正在重新评估公司的业务前景，导致股价出现明显下跌。然而，目前Hims &amp; Hers Health尚未就股价变动发表官方声明，具体影响还有待进一步观察。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health夜盘大跌近8%，FDA终止复方仿制药上市政策</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health夜盘大跌近8%，FDA终止复方仿制药上市政策\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-05-22 08:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>5月22日，数字医疗保健公司Hims &amp; Hers Health Inc.（股票代码：HIMS）在周三夜盘交易中遭遇重创，股价大跌近8%。这一显著下跌引发了市场的广泛关注，投资者们纷纷猜测其背后的原因。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/855466511362b16d9ef396717e875486\" tg-width=\"865\" tg-height=\"831\"/></p><p>分析人士指出，此次股价下跌可能与近期减肥药市场的重大政策变化有关。大型保险公司Cigna宣布将在其药房福利管理计划中引入新条款，为使用热门减肥药Wegovy和Zepbound的患者提供每月200美元的自付费用上限。这一举措可能会影响到Hims &amp; Hers等公司在竞争激烈的减肥药市场中的地位，从而引发投资者对公司未来业绩的担忧。</p><p>此外，美国食品和药物管理局（FDA）允许销售复方制剂Wegovy和Zepbound的政策将于5月22日结束，这一变化可能会直接影响Hims &amp; Hers等公司销售这些产品的能力。随着政策环境的变化，投资者似乎正在重新评估公司的业务前景，导致股价出现明显下跌。然而，目前Hims &amp; Hers Health尚未就股价变动发表官方声明，具体影响还有待进一步观察。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1148052920","we_media_id":"1092702339","thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148052920","pubTimestamp":1747872166,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"数字医疗保健公司Hims & Hers Health Inc.在周三夜盘交易中遭遇重创，股价大跌6.21%。这一显著下跌引发了市场的广泛关注，投资者们纷纷猜测其背后的原因。分析人士指出，此次股价下跌可能与近期减肥药市场的重大政策变化有关。这一举措可能会影响到Hims & Hers等公司在竞争激烈的减肥药市场中的地位，从而引发投资者对公司未来业绩的担忧。然而，目前Hims & Hers Health尚未就股价变动发表官方声明，具体影响还有待进一步观察。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Hims & Hers Health fell nearly 8% in night trading, FDA terminated compound generic drug listing policy","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/edc2ef25ae9b898c3f9959254b6710a2","symbols_score_info":{"HIMS":1},"content_text":"5月22日，数字医疗保健公司Hims & Hers Health Inc.（股票代码：HIMS）在周三夜盘交易中遭遇重创，股价大跌近8%。这一显著下跌引发了市场的广泛关注，投资者们纷纷猜测其背后的原因。分析人士指出，此次股价下跌可能与近期减肥药市场的重大政策变化有关。大型保险公司Cigna宣布将在其药房福利管理计划中引入新条款，为使用热门减肥药Wegovy和Zepbound的患者提供每月200美元的自付费用上限。这一举措可能会影响到Hims & Hers等公司在竞争激烈的减肥药市场中的地位，从而引发投资者对公司未来业绩的担忧。此外，美国食品和药物管理局（FDA）允许销售复方制剂Wegovy和Zepbound的政策将于5月22日结束，这一变化可能会直接影响Hims & Hers等公司销售这些产品的能力。随着政策环境的变化，投资者似乎正在重新评估公司的业务前景，导致股价出现明显下跌。然而，目前Hims & Hers Health尚未就股价变动发表官方声明，具体影响还有待进一步观察。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}